Ondine Biomedical (AIM:OBI) said NHS Golden Jubilee has become the first hospital in Scotland to adopt its Steriwave nasal photodisinfection treatment, working alongside UK distribution partner Mölnlycke Health Care.
Ondine develops light-activated antimicrobial therapies aimed at preventing hospital-acquired infections.
NHS Golden Jubilee carries out around 30% of Scotland's hip and knee replacements, giving the rollout outsized reach across the country's elective orthopaedic pathway.
Steriwave is a five-minute, clinician-administered treatment given immediately before surgery, using a light-activated agent and red light to reduce pathogens in the nose, a known source of surgical site infections.
The approach replaces multi-day home decolonisation regimens and avoids antibiotics.
UK research cited by Ondine found that revision surgery following a prosthetic joint infection after primary hip replacement adds around £33,000 in inpatient and day-case costs over five years compared with uncomplicated cases.
Standard joint replacements at NHS Golden Jubilee average a 2.4-day hospital stay, meaning fewer infections translate directly into freed-up bed capacity.
"By integrating nasal photodisinfection into our infection-prevention bundle, we offer an efficient, nurse-led solution that enhances patient outcomes and optimises healthcare resources," said Professor Christopher Gee, consultant orthopaedic surgeon at NHS Golden Jubilee.
Ondine CEO Carolyn Cross said the adoption supports Scotland's health strategy by protecting both patients and surgical capacity across the NHS.
News Intelligence what this means for the company
Ondine Biomedical's Steriwave nasal photodisinfection has been adopted by NHS Golden Jubilee, Scotland's largest hip and knee replacement centre, handling ~30% of the country's elective orthopaedic volume. The five-minute pre-surgery treatment replaces multi-day home decolonisation and avoids antibiotics, directly addressing a high-cost failure mode: revision surgery for prosthetic joint infection costs ~£33,000 more over five years than uncomplicated cases. This is Ondine's first Scottish hospital adoption and represents a material foothold in a high-volume, cost-sensitive NHS pathway where bed-day savings reinforce clinical value.
- Mölnlycke Health Care, Ondine's UK distribution partner named in the announcement, now has a flagship NHS reference site in Scotland's largest orthopaedic centre, potentially accelerating uptake across other UK trusts.
This adoption validates Steriwave's clinical and operational fit in high-volume elective surgery—a different patient population and use case from the ICU pneumonia focus of the LANTERN Phase 3 study. Success at Golden Jubilee, with its outsized reach and documented cost-benefit case, could establish a replicable NHS orthopaedic pathway ahead of any US regulatory decision, diversifying Ondine's revenue streams and de-risking dependence on a single indication.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
